CoChat
Sign Up
Cited by 386Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer TreatmentsPARP inhibition in cancer therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

Rose, P G, Blessing, J A, Mayer, A R, Homesley, H D·1998·Journal of Clinical Oncology
DOI 10.1200/jco.1998.16.2.405
Open this paper in CoChat — free account

Abstract

PURPOSE: A phase II trial was conducted to determine the activity of prolonged oral etoposide in platinum-resistant and platinum-sensitive ovarian carcinoma. PATIENTS AND METHODS: Platinum-resistant disease was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. The starting dose was 50 mg/m2/d (30 mg/m2/d for prior radiotherapy) for 21 days, every 28 days. A dose escalation to a maximum dose of 60 mg/m2/d was prescribed. RESULTS: Of 99 patients entered, 97 were assessable for toxicity and 82 were assessable for response. Among 41 platinum-resistant patients a 26.8% response rate (7.3% complete response [CR] and 19.5% partial response [PR] rate) occurred. The median response duration was 4.3 months (range, 1.3 to 8.7), median progression-free interval (PFI) was 5.7 months (range, 0.8 to 30.8+), and median survival time was 10.8 months (range, 1.9 to 45.8). Twenty-five of 41 platinum-resistant patients had also previously received paclitaxel; of which eight (32%) responded. Among 41 platinum-sensitive patients, a 34.1% response rate (14.6% CR and 19.5% PR rate) occurred. The median response duration was 7.5 months (range, 1.9 to 15.2+), median PFI was 6.3+ months (range, 0.9 to 20.4), and median survival time was 16.5+ months (range, 0.9 to 34.8). Of 97 patients assessable for toxicity, grade 3 or 4 hematologic toxicity was common, with leukopenia occurring in 41.2% (grade 3, 29%; grade 4, 12%), neutropenia in 45.4% (grade 3, 20%; grade 4, 25%), thrombocytopenia in 9% (grade 3, 5%; grade 4, 4%), and anemia in 13.4%. Three treatment-related deaths occurred: two from neutropenic sepsis and one from thrombocytopenic bleeding after an overdose. One patient developed leukemia. CONCLUSION: This regimen is active in platinum-resistant and platinum-sensitive ovarian carcinoma. Additionally, the regimen is active in paclitaxel-resistant ovarian carcinoma.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.1998.16.2.405

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Rose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D.
Affiliations
  • University Hospitals of Cleveland (US)
  • Case Western Reserve University (US)
ORCID
Rose, P G
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
1998-02
Volume
16
Issue
2
Pages
405-410
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.1998.16.2.405
OpenAlex
W1543697093
Cited by
386
References
29
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 7 · 2022: 8 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 9 · 2014: 10 · 2013: 16 · 2012: 14
FWCI
20.55
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA27469, U10CA037517, U10CA027469, (CA 37517)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
etoposide, oral etoposide, second-line chemotherapy, paclitaxel, hematologic toxicity, neutropenia, thrombocytopenia, non-relapse mortality, response rate, progression-free survival, dose escalation
MeSH terms
Adenocarcinoma, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Carcinoma, Etoposide, Female, Humans, Middle Aged, Ovarian Neoplasms, Platinum Compounds, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review